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Abstract
Background: Health databases are a promising resource for epidemiological studies on medications safety during
pregnancy. The reliability of information on medications exposure and pregnancy timing is a key methodological
issue. This study (a) compared maternal self-reports and database information on medication use, gestational age,
date of delivery; (b) quantified the degree of agreement between sources; (c) assessed predictors of agreement.
Methods: Pregnant women recruited in a prenatal clinic in Friuli Venezia Giulia (FVG) region, Italy, from 2007 to
2009, completed a questionnaire inquiring on medication use during pregnancy, gestational age and date of
delivery. Redeemed prescriptions and birth certificate records were extracted from regional databases through
record linkage. Percent agreement, Kappa coefficient, prevalence and bias-adjusted Kappa (PABAK) were calculated.
Odds Ratio (OR), with 95 % confidence interval (95 % CI), of ≥1 agreement was calculated through unconditional
logistic regression.
Results: The cohort included 767 women, 39.8 % reported medication use, and 70.5 % were dispensed at least one
medication. Kappa and PABAK indicated almost perfect to substantial agreement for antihypertensive medications
(Kappa 0.86, PABAK 0.99), thyroid hormones (0.88, 0.98), antiepileptic medications (1.00, 1.00), antithrombotic agents
(0.70, 0.96). PABAK value was greater than Kappa for medications such as insulin (Kappa 0.50, PABAK 0.99), antihistamines
for systemic use (0.50, 0.99), progestogens (0.28, 0.79), and antibiotics (0.12, 0.63). Adjusted OR was 0.48 (95 % CI 0.26; 0.90)
in ex- vs. never smokers, 0.64 (0.38; 1.08) in < high school vs. university, 1.55 (1.01; 2.37) in women with comorbidities, 2.25
(1.19; 4.26) in those aged 40+ vs. 30–34 years.
Gestational age matched exactly in 85.2 % and date of delivery in 99.5 %.
(Continued on next page)
* Correspondence: federica.pisa@uniud.it
1Institute of Hygiene and Clinical Epidemiology, University Hospital of Udine,
Via Colugna 50, 33100 Udine, Italy
2Department of Medical and Biological Sciences, University of Udine, Udine,
Italy
Full list of author information is available at the end of the article
© 2015 Pisa et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pisa et al. BMC Pregnancy and Childbirth  (2015) 15:310 
DOI 10.1186/s12884-015-0745-3
(Continued from previous page)
Conclusions: For selected medications used for chronic conditions, the agreement between self-reports and dispensing
data was high. For medications with low to very low prevalence of use, PABAK provides a more reliable measure of
agreement. Maternal reports and dispensing data are complementary to each other to increase the reliability of
information on the use of medications during pregnancy. Birth certificates provide reliable data on the timing of
pregnancy. FVG health databases are a valuable source of data for pregnancy research.
Keywords: Pregnancy, Medication use, Health database, Dispensing claims, Birth certificate, Agreement, Kappa,
Prevalence and bias-adjusted Kappa, Pharmacoepidemiology, Questionnaires
Background
Maternal use of prescription medications during preg-
nancy is common, with prevalence ranging from 27 to
99 % in developed countries [1]. In Italy, a prevalence of
about 50 % has been reported [2].
Pregnant women are generally not included in pre-
authorization studies, thus the risk–benefit profile of
medicines used in pregnancy is assessed mostly through
post-authorization studies. The assessment of the associ-
ation between maternal use of medications during preg-
nancy and pregnancy or infant outcomes often rely on
pregnancy medication exposure registries [3, 4] and on
studies using administrative databases [5–7], registering
prescriptions at the general physician prescription level
or at pharmacy dispensing level.
Pregnancy registries can provide timely ascertainment
of exposure and outcomes, and good quality information
on their temporal association when data are collected
prospectively. Limitations include: (a) potential for selec-
tion bias, as registration is spontaneous, (b) insufficient
power for some outcomes, (c) problems in identifying an
appropriate comparison group, (d) quality and complete-
ness of information depends on healthcare providers
and/or maternal reporting [8].
Administrative databases represent an efficient and
cost-effective source of data on large populations, and
they allow researchers to identify exposure, regardless of
information on outcome [9]. However their use in asses-
sing medication exposure has some limitations. In par-
ticular, prescription filling or redemption is a proxy for
medication consumption. Noncompliance and medica-
tion borrowing or sharing [10] may lead to overesti-
mation of use and exposure misclassification. It has been
estimated that 6 % of dispensed medications were not
used [11]. Moreover, information on the use of non-
prescription and over- the- counter (OTC) medications,
herbal preparations and medications taken in the hos-
pital, is not captured.
Other approaches include case–control studies/sur-
veillance, and cohort studies. In ad hoc studies, maternal
self-reports have often been used to measure medication
use in pregnancy. Inaccurate recall, susceptibility to bias
and under-reporting are among the limitations of this
tool. The accuracy of reporting has been shown to vary
by therapeutic class [12], type of use (chronic vs. occa-
sional) [13] and to depend on data collection methods
and questionnaire design [14–16].
Due to the limitations of maternal self-reports and pre-
scription databases, neither of these sources can be consid-
ered the ‘gold standard’ to assess the use of medications.
Several studies compared self-reported and database
information on medication use [17–19], in specific sub-
groups, such as the elderly [20, 21], adolescents [22],
hypertensive patients [16], or for specific medications or
therapeutic classes, such as oral contraceptives [23], hor-
mone replacement therapy [24], psychoactive medica-
tions [25], nonsteroidal anti-inflammatory drugs [26].
Few studies have been conducted in pregnant women,
comparing maternal reports of medication use during
pregnancy and database information [12, 14, 27–30]. In
general, the results showed that medications taken for
long courses or chronically, such as antidiabetic agents,
medications for thyroid conditions and for asthma, anti-
epileptics and antihypertensives, had generally higher
agreement than medications taken occasionally.
Another key methodological issue is the accuracy of
information on the use of medications during pregnancy
and on pregnancy timing. The latter is needed to assign
etiologically relevant ‘time windows’ of exposure to
medication at the exact gestational age.
In a cohort of 767 women, resident of Friuli Venezia
Giulia (FVG) region, Northeast Italy, and recruited from
2007 to 2009 at the first visit in a prenatal clinic, we
compared (a) self-reported information on medication
use during pregnancy with data from the regional out-
patient dispensing database; and (b) self-reported infor-
mation on gestational age at birth and on date of
delivery with data from the birth certificate database.
Moreover, we assessed the effect of women characteris-
tics on the likelihood of agreement.
Methods
Data sources
The sources of data were selected FVG health databases,
recording computerized information on the use of health
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services for the residents of the region. All residents are
registered with the Regional Health System, providing
universal access to health care. A unique personal identi-
fier links anonymized individual records. For this study,
the outpatient dispensing and birth certificate databases
were used.
The database used in this study records prescriptions
at pharmacy redemption level. The database captures all
redeemed prescriptions for reimbursed medications dis-
pensed to residents of the region. Prescription medica-
tions are reimbursed to residents, including pregnant
women.
For each redeemed prescription, the following infor-
mation is recorded: date of redemption, active substance
(description and Anatomical Therapeutic and Chemical
ATC classification code [31]), brand, quantity, strength,
dispensed form, number of units and number of refills.
Information on the indication and the prescribed dosage
regimen are not recorded.
The birth certificate database records data on all births
in FVG since 1989. For each birth, the information re-
corded includes: gestational age at the first prenatal visit,
at the first ultrasound examination and at delivery, date
of delivery, number of prenatal visits and ultrasound
examinations, gestational hypertension.
The Direzione Centrale Salute, Integrazione Socio
Sanitaria e Politiche Sociali, Regione Friuli Venezia
Giulia granted permission to access all above men-
tioned anonymized databases.
Study cohort
Pregnant women attending their first prenatal visit (be-
tween 20 and 22 weeks of gestation) at the Institute for
Maternal and Child Health - IRCCS “Burlo Garofolo”, in
Trieste, FVG, from April 3, 2007 to March 3, 2009 were
eligible to be included in this prospective cohort. Eligible
women had to be resident in FVG for at least 2 years, in
order to be covered by the regional health databases for
a period of time before pregnancy, as another objective
of this study was to assess the effect of maternal medica-
tion and behavioral exposures before pregnancy on the
health of the mother and child. Moreover, women had
to be fluent in Italian and at least 18 years old. Women
with complicated or twin pregnancies were excluded.
Complicated pregnancies were defined as those with
maternal abnormalities of the reproductive tract, uterine
fibroids, pre-existing chronic illness such as cancer,
AIDS, severe heart disease, severe kidney disease, severe
Crohn’s disease or ulcerative colitis, and those with
foetal congenital defects. A complicated pregnancy was
determined at the time of recruitment. According to
protocol, when a complication emerged in a prenatal
examination (e.g. a prenatal tests indicated that the
foetus had congenital defects), the woman was excluded
from the study. However, no women were excluded for a
complicated pregnancy, or any other reason, after re-
cruitment. All eligible women recruited in the study
were included in statistical analysis.
During the recruitment period, about 1800 live births
per year were recorded in Trieste and 9000 in FVG [32].
Data collection
Women who agreed to participate filled in a self-
administered questionnaire between the 28th week of es-
timated gestational age and 1 month after delivery. The
questionnaire inquired on the use of medications during
the pregnancy. Women answering ‘Yes’ to the question
‘Have you ever taken medications – on a regular basis -
during pregnancy?’ were asked to indicate the brand
name and/or the name of the active substance and the
indication. (‘Which medications have you used during
pregnancy? Please list the commercial name of each
medication, active substance, if known, and its indica-
tion’). In the instructions for completing the questions,
‘regular basis’ was defined as ‘the assumption of a medi-
cation for 4 or more times per week or for more than
two weeks’.
Data on brand name, active substance and indication
of up to six medications were collected. The questions
were open-ended.
The questionnaire collected also information on
women social and demographic characteristics (country
of origin, age, level of education, marital status and pro-
fession), health behaviours and conditions (smoking,
comorbidities before or during pregnancy, such as dia-
betes, asthma, allergy, epilepsy, hypertension, vomit,
hypothyroidism, hyperthyroidism, lupus, rheumatic dis-
eases, urinary infections, infections, fever, seizures,
anemia, cardiovascular diseases, neurological diseases),
prior pregnancies (gravidity), gestational age at birth and
date of delivery. The date of questionnaire completion
was also recorded. The questionnaire is provided as an
Additional file 1.
For each woman, through record linkage using an in-
dividual identifier, we extracted from health databases
the records of (a) prescriptions redeemed from 2006 to
2012 and (b) birth certificate. All prescriptions redeemed
from the estimated date of conception to the date of
delivery were considered during the pregnancy. The esti-
mated date of conception was obtained by subtracting
gestational age at birth from the date of delivery.
Because of the lack of a true gold standard, the agree-
ment between questionnaire self-reports and prescrip-
tions redemption data was evaluated by means of Kappa
coefficient [33], with 95 % confidence interval (95 % CI)
based on asymptotic standard error. Kappa values were
interpreted according to Landis and Koch categorization
[34] as almost perfect (>0.80), substantial (0.61-0.80),
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moderate (0.41-0.60), fair (0.21-0.40), slight (0.00-0.20)
and poor (<0.00). Prevalence and bias indices and preva-
lence and bias-adjusted Kappa (PABAK) [35] were calcu-
lated. A SAS macro [36] was used for this analysis.
To help the interpretation of the Kappa values, we also
calculated sensitivity, specificity, positive and negative pre-
dictive value, with 95 % confidence interval (95 % CI). The
prescription database was the reference standard. Confi-
dence intervals were calculated according to the method
by Wilson [37] to avoid aberrations.
For women who completed the questionnaire before
the delivery, the prescriptions dispensed from the esti-
mated date of conception to the date of questionnaire
completion were considered for the assessment of
agreement.
The same statistics were calculated to assess the agree-
ment between hypertension during pregnancy reported
in questionnaire and recorded in the birth certificate
database. Hypertension during pregnancy, both reported
in questionnaire and recorded in the birth certificate
database, was also compared with the use antihyperten-
sive medications, both reported and recorded in the
dispensing database.
The Odds Ratio (OR), with 95 % CI, of having at least
one agreement between questionnaire and prescription
database was calculated through unconditional logistic
regression. The following variables were evaluated
through uni- and multi-variable analysis: age at delivery,
level of education, prior pregnancies, smoking status, co-
morbidities during pregnancy, country of origin, time of
completion, marital status, number of visits and of ultra-
sound imaging during pregnancy, number of medica-
tions reported in questionnaire. The manual process of
multivariate model building included entering individual
terms and evaluating the likelihood ratio test for inclusion
of each variable in the model. Only variables that ex-
plained the variability or modified the regression coeffi-
cient estimators were retained. The final model included
age at delivery, level of education, prior pregnancies,
smoking status, and comorbidities during pregnancy and
country of origin. Women who did not report any medica-
tion use and without any prescription, were excluded from
this analysis.
The percentage of women matching exactly or with ±1
and ±2 days of difference, on the date of delivery and
gestational age at birth was calculated.
The statistical analysis was performed with SAS© soft-
ware, version 9.3 (SAS, Cary, NC, USA).
Ethics committee review
The study protocol was approved by the Ethics Com-
mittees at the University Hospital of Udine and at the
Institute for Maternal and Child Health of Trieste.
Written informed consent for participation in the
study was obtained.
Results
The cohort included 767 women of whom, 305 (39.8 %)
reportedly used medications during pregnancy (Table 1).
In this group, the percentages of women aged ≥35 years
at delivery (41.2 % vs. 34.4 %), of primiparae (46.6 % vs.
44.5 %) and of never smokers (62.3 % vs. 53.3 %) were
higher than those among nonusers. Users also reported
more prenatal visits (≥8: 67.9 % vs. 64.2 %) and ultra-
sound examinations (≥5: 58.0 % vs. 54.3 %) than nonu-
sers. Seven women did not complete the question on
medication use. Only 5 (0.65 %) women reported 6 med-
ications, 5 (0.65 %) reported 5 and 152 (19.8 %) reported
the use of only 1 medication. The median number of
medications reported was 1 (25°; 75° percentile: 1; 2) and
the mean was 1.8 (standard deviation 1.09).
Overall, 70.5 % of women (N = 541) redeemed at least
one prescription during the pregnancy. Only 2 women
were dispensed more than 6 different medications (one
7 and one 9). The median number of dispensing was 2
(25°; 75° percentile: 1; 2), the mean was 1.8 (standard de-
viation 1.01). Folic acid (36.0 % of women reported the
use and 29.0 % had at least one dispensing) and iron
(26.2 % and 28.6 %) were the most frequently used medi-
cations (Table 2). A total of 146 women (19.2 %) were
dispensed antibiotics and 96 (12.6 %) progestogens, but
only 20 (2.6 %) and 19 (2.5 %), respectively, reported
their use. Of note, 5 women were dispensed antidepres-
sants and one methadone. The use of these medications
was not reported.
Kappa and PABAK values indicated almost perfect to
substantial agreement for antihypertensive medications
(Kappa 0.86 and PABAK 0.99), thyroid hormones (0.88
and 0.98), antiepileptic medications (1.00 and 1.00), anti-
thrombotic agents (0.70 and 0.96).
Except for iron (PABAK 0.59), all medications with
Kappa 0.60 to 0.21, indicating moderate to fair agree-
ment, had PABAK ≥0.79, e.g. insulin (Kappa 0.50 and
PABAK 0.99), antihistamines for systemic use (0.50 and
0.99) and progestogens (0.28 and 0.79).
Except for folic acid (Kappa 0.11 and PABAK 0.22),
PABAK was higher than Kappa when this latter indi-
cated slight agreement, such as for antibiotics (0.12
and 0.63), labour repressants (0.18 and 0.98) and
medications for acid related disorders (0.17 and 0.81).
When Kappa indicated poor agreement, e.g. for non-
steroidal anti-inflammatory drugs, non-opioid analgesics
or selective serotonin agonists, PABAK was >0.80. The re-
sults did not vary when Kappa and PABAK were calcu-
lated separately according to the time of questionnaire
completion (i.e. before or after the delivery) (Additional
file 2: Table S1).
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Table 1 Women characteristics by questionnaire self-reported use of medications
Questionnaire-reported use of medications
Users Non users Not reported Chi
square pa
Total
(N = 305) (N = 455) (N = 7) (N = 767)
N % N % N % N %
Age at delivery (years)
<25 20 6.6 22 4.8 0 - 0.1954 42 5.5
25-29 42 13.8 68 14.9 1 14.3 111 14.5
30-34 117 38.4 209 45.9 1 14.3 327 42.6
35-39 100 32.7 125 27.6 4 57.1 229 29.8
40+ 26 8.5 31 6.8 1 14.3 58 7.6
Prior pregnanciesb
None 142 46.6 202 44.5 4 57.1 0.0182 348 45.4
1-2 131 42.9 226 49.8 2 28.6 359 46.8
3+ 32 10.5 25 5.5 1 14.3 58 7.6
Marital statusc
Married 275 90.2 401 88.4 7 100.0 0.4642 683 89.0
Single 28 9.2 49 10.5 0 - 77 10.0
Level of educationc
< High school 48 15.7 88 19.4 3 42.9 0.1480 139 18.1
High school 140 45.9 222 48.8 2 28.6 364 47.5
University 116 38.0 144 31.7 2 28.6 262 34.2
Country of originc
Italy 279 91.5 415 91.4 7 100.0 0.9429 701 91.4
Other 24 7.9 35 7.7 0 - 59 7.8
Working statusc
Employed on maternity leave 225 73.8 338 74.3 5 71.4 0.7015 568 74.0
Currently employed 22 7.2 35 7.7 0 - 57 7.4
Housewife 26 8.5 39 8.6 2 28.6 67 8.7
Unemployed 20 6.6 42 9.2 0 - 62 8.1
Occupation
Armed forces occupations 2 0.7 2 0.4 - - 0.0044 4 0.5
Manager 16 5.2 13 2.9 - - 29 3.8
Professional 16 5.2 51 11.2 - - 67 8.7
Technicians and associate professionals 35 11.5 62 13.6 - - 97 12.6
Clerical support workers 108 35.4 191 42.0 3 42.9 302 39.4
Service and sales workers 38 12.5 34 7.5 1 14.3 73 9.5
Craft and related trades workers 14 4.6 21 4.6 - - 34 4.4
Plant and machine operators, and assemblers 10 3.3 11 2.4 - - 21 2.7
Elementary occupations 23 7.5 17 3.7 - - 40 5.2
Prenatal care visits (number)
<7 50 16.4 98 21.5 3 42.9 0.2215 151 19.7
7 48 15.7 65 14.3 2 28.6 115 15.0
8 61 20.0 100 22.0 1 14.3 162 21.1
9 or more 146 47.9 192 42.2 1 14.3 339 44.2
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For all medications, the sensitivity of questionnaire vs.
database was lower than specificity, and the negative
predictive value was >0.90 with the exceptions of iron
(0.84), folic acid (0.75), progestogens (0.89), antibiotics
(0.82) (Table 3).
When simultaneously adjusted for age at delivery, level
of education, prior pregnancies, smoking status, comor-
bidities during pregnancy and country of origin, the OR
of ≥1 agreement was 0.88 (95 % CI 0.46- 1.67) in immi-
grant vs. Italy-born women, 0.48 (95 % CI 0.26- 0.90) in
ex-smokers having quit during or after the pregnancy
and 0.66 (95 % CI 0.36- 1.21) in current vs. never
smokers (Table 4). The OR was 0.75 (95 % CI 0.53-
1.09) and 0.64 (95 % CI 0.38- 1.08) in women with high
school and < high school, respectively, vs. those with a
university degree.
Women experiencing comorbidities during the preg-
nancy (OR 1.55, 95 % CI 1.01- 2.37), primiparae (OR 1.50,
95 % CI 1.07- 2.11) and those aged 40+ years (OR 2.25, 95
% CI 1.19- 4.26) vs. those aged 30–34 years, were signifi-
cantly more likely to have ≥1agreement. The OR was also
increased in women aged <25 (OR 2.25, 95 % CI 1.06-
4.79) and 35 to 39 years (OR 1.33, 95 % CI 0.90- 1.97).
Agreement was more likely with an increasing number
of medications reported: compared to women reporting
the use of 1 medication during pregnancy, the OR of
having at least one agreement was 2.53 (95 % CI 1.39;
4.59) in those reporting 2, and 3.81 (95 % CI 1.74; 8.34)
in those reporting 3 or more medications.
Gestational age matched exactly in 85.2 % of women
(±1 or 2 days in 14.6 %) and date of delivery in 99.5 %
(±1 day in 0.5 %) (Table 5). For number of prenatal visits
and number of ultrasound examinations, concordance
(±1) was 54.7 % and 57.2 %, respectively.
Hypertension during pregnancy was reported by 33
(4.3 %) women but only 15 had this condition recorded
in the birth certificate database (Kappa 0.40; 95 % CI
0.22-0.58; PABAK 0.92). Dispensing for antihypertensive
medications had a positive predictive value (PPV) of
100 % for both self-reported and recorded hypertension
and a negative predictive value (NPV) of 96.4 % (95 % CI
95.0-97.8) and 98.9 % (95 % CI 98.2-99.6), respectively
(Additional file 1: Tables S2-S3).
Discussion
About 40 % of women reported the use of medications
and about 70 % redeemed at least one prescription during
pregnancy. The agreement between self-reported data and
database information varied greatly by therapeutic class. It
was almost perfect to substantial for medications taken
for chronic conditions, such as antihypertensive medica-
tions, thyroid hormones, antiepileptic and antithrombotic
medications, while it was moderate to slight for OTC
medications, such as iron and folic acid. These results are
consistent with prior studies [12, 28–30]. Medications
such as antibiotics or antivirals, taken occasionally,
showed slight to fair Kappa-based agreement but, when
prevalence and bias were taken into account, the agree-
ment was higher. A prior study found high agreement for
antibiotics [38]. The Kappa coefficient is influenced by the
prevalence of the condition and by bias. Its value, there-
fore, was interpreted in the light of additional indices of
agreement, such as PABAK. For several medications
showing moderate to poor agreement, such as agents for
obstructive airways disease and for acid related disorders,
progestogens, labour repressants, non-opioid analgesics
and antidepressants, the value of these indices suggested
Table 1 Women characteristics by questionnaire self-reported use of medications (Continued)
Prenatal ultrasound imaging (number)
<4 72 23.6 131 28.8 3 42.9 0.0425 206 26.9
4 56 18.4 77 16.9 1 14.3 134 17.5
5 to 7 79 25.9 139 30.6 2 28.6 220 28.7
8 or more 98 32.1 108 23.7 1 14.3 207 27.0
Smoking statusc
Never smoker 190 62.3 242 53.3 4 57.1 0.0557 436 56.8
Current smoker 25 8.2 47 10.3 1 14.3 73 9.5
Ex-smoker, quitted before pregnancy 64 20.9 112 24.7 1 14.3 177 23.1
Ex-smoker, quitted during or after pregnancy 21 6.9 49 10.8 1 14.3 71 9.3
Prescriptions redeemed during pregnancy
Yes 243 79.7 285 62.6 5 71.4 <.0001 541 70.5
No 62 20.3 170 37.4 2 28.6 226 29.5
a Comparing users and non users
b Prior pregnancies refer to gravidity
c The percentages may not sum to 100 % due to missing data
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Table 2 Number of women classified as users by questionnaire and prescription redemption database, by therapeutic class, Kappa
coefficient (Kappa), with 95 % confidence interval, strength of agreement, Positive and Negative Agreement, Prevalence Index, Bias
Index, Prevalence and Bias adjusted Kappa (PABAK)
Users Kappa 95 % CIa Strength of
Agreementb
Positive
Agreement
Negative
Agreement
Prevalence
Index
Bias
Index
PABAK
Questionnaire database
Therapeutic class ATCc N % N %
Alimentary tract and metabolism
Medications for
acid related disorders
A02 27 3.6 66 8.7 0.17 0.06; 0.29 slight 0.21 0.95 −0.879 −0.051 0.81
Antacids A02A 21 2.8 28 3.7 0.18 0.02; 0.33 slight 0.20 0.97 −0.935 −0.009 0.90
Medications for
peptic ulcer and
gastro-oesophageal reflux
A02B 7 0.9 42 5.5 0.15 0.01; 0.29 slight 0.16 0.97 −0.935 −0.046 0.89
Medications for
functional gastrointestinal
disorders
A03 12 1.6 0 - 0.00 - - poor 0.00 0.99 −0.984 0.016 0.97
Bile and liver therapy A05 2 0.3 3 0.4 0.40 −0.15; 0.94 fair 0.40 0.99 −0.993 −0.001 0.99
Laxatives and
antidiarrheals
A06 4 0.5 1 0.1 0.00 −0.00; 0.00 poor 0.00 0.99 −0.993 0.004 0.99
Insulin A10A 1 0.1 3 0.4 0.50 −0.10; 1.00 moderate 0.50 0.99 −0.995 −0.003 0.99
Vitamins and mineral
supplements
A11,
A12
18 2.4 6 0.8 0.00 −0.02; 0.00 poor 0.00 0.98 −0.968 0.016 0.94
Blood and blood forming organs
Antithrombotic agents B01 24 3.2 32 4.2 0.70 0.57; 0.84 substantial 0.71 0.99 −0.926 −0.010 0.96
Heparins B01AB 14 1.8 23 3.0 0.64 0.46; 0.82 substantial 0.65 0.99 −0.951 −0.012 0.97
Platelet aggregation
inhibitors
B01AC 14 1.8 12 1.6 0.76 0.58; 0.95 substantial 0.77 0.99 −0.966 0.003 0.98
Antihemorrhagics B02 0 - 5 0.7 0.00 - - poor 0.00 0.99 −0.993 −0.007 0.99
Iron B03A 199 26.2 217 28.6 0.49 0.42; 0.56 moderate 0.63 0.86 −0.452 −0.024 0.59
Folic acid B03B 273 36.0 220 29.0 0.11 0.04; 0.18 slight 0.40 0.71 −0.355 0.070 0.22
Solutions B05BB 0 - 2 0.3 0.00 - - poor 0.00 0.99 −0.99 −0.001 0.99
Cardiovascular system
Antihypertensive
medications
C02, C07,
C08, C09A
6 0.8 8 1.0 0.86 0.66; 1.00 almost
perfect
0.86 0.99 −0.98 −0.003 0.99
Methyldopa C02 0 - 1 0.1 0.00 - - poor 0.00 0.99 −0.99 −0.001 0.99
Beta-blocking agents C07 3 0.4 3 0.4 1.00 1.00; 1.00 almost
perfect
1.00 1.00 −0.99 0.000 1.00
Calcium channel
blockers
C08 5 0.7 7 0.9 0.83 0.60; 1.00 almost
perfect
0.83 0.99 −0.98 −0.003 0.99
Ace inhibitors C09A 0 - 1 0.1 0.00 - - poor 0.00 0.99 −0.99 −0.001 0.99
Lipid modifying agents C10A 0 - 1 0.1 0.00 - - poor 0.00 0.99 −0.99 −0.001 0.99
Diuretics C03 0 - 2 0.3 0.00 - - poor 0.00 0.99 −0.99 −0.003 0.99
Vasoprotectives C05C 2 0.3 0 - 0.00 - - poor 0.00 0.99 −0.99 0.003 0.99
Genito-urinary system and sex hormones
Gynaecological
antiinfectives - antiseptics
G01A 7 0.9 0 - 0.00 - - poor 0.00 0.99 −0.991 0.009 0.98
Sympathomimetics,
labour repressants
G02CA 10 1.3 1 0.1 0.18 −0.12;
0.48
slight 0.18 0.99 −0.985 0.012 0.98
Prolactin inhibitors G02CB 0 - 3 0.4 0.00 - - poor 0.00 0.99 −0.996 −0.004 0.99
Hormonal
contraceptives
G03A 0 - 2 0.3 0.00 - - poor 0.00 0.99 −0.997 −0.003 0.99
Estrogens G03C 0 - 3 0.4 0.00 - - poor 0.00 0.99 −0.996 0.004 0.99
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Table 2 Number of women classified as users by questionnaire and prescription redemption database, by therapeutic class, Kappa
coefficient (Kappa), with 95 % confidence interval, strength of agreement, Positive and Negative Agreement, Prevalence Index, Bias
Index, Prevalence and Bias adjusted Kappa (PABAK) (Continued)
Progestogens G03D 19 2.5 96 12.6 0.28 0.18; 0.39 fair 0.31 0.94 −0.848 −0.104 0.79
Gonadotrophins G03G 0 - 3 0.4 0.00 - - poor 0.00 0.99 −0.996 −0.004 0.99
Systemic hormonal preparations
Glucocorticoid, systemic H02A 5 0.7 9 1.2 0.28 −0.03; 0.59 fair 0.29 0.99 −0.982 −0.005 0.97
Thyroid preparations H03 35 4.6 39 5.1 0.86 0.77; 0.94 almost
perfect
0.86 0.99 −0.902 −0.005 0.97
Thyroid hormones H03A 33 4.3 39 5.1 0.88 0.80; 0.96 almost
perfect
0.89 0.99 −0.905 −0.008 0.98
Antithyroid preparations H03B 2 0.3 0 - 0.00 - - poor 0.00 0.99 −0.997 0.003 0.99
Anti-infective agents
Antibiotics, systemic J01 20 2.6 146 19.2 0.12 0.05; 0.18 slight 0.16 0.90 −0.781 −0.166 0.63
Antimycotics, systemic J02 1 0.1 4 0.5 0.40 −0.14; 0.94 fair 0.40 0.99 −0.993 −0.004 0.99
Antivirals, systemic J05 1 0.1 5 0.7 0.33 −0.15; 0.82 fair 0.33 0.99 −0.992 −0.005 0.99
Immune sera and
immunoglobulins
J06B 0 - 6 0.8 0.00 - - poor 0.00 0.99 −0.992 −0.008 0.98
Musculo-skeletal system
Non-steroidal anti-
inflammatory drugs
M01A 2 0.3 11 1.4 0.00 −0.01; 0.00 poor 0.00 0.99 −0.983 −0.012 0.97
Bisphosphonates M05B 0 - 1 0.1 0.00 - - poor 0.00 0.99 −0.999 −0.001 0.99
Nervous system
Non-opioid analgesics N02BE 47 6.2 2 0.3 0.00 −0.01; 0.00 poor 0.00 0.97 −0.935 0.059 0.87
Selective serotonin
agonists
N02CC 1 0.1 2 0.3 0.00 −0.00; 0.00 poor 0.00 0.99 −0.996 −0.001 0.99
Antiepileptic
medications
N03 1 0.1 1 0.1 1.00 1.00; 1.00 almost
perfect
1.00 1.00 −0.997 0.000 1.00
Antidepressants N06A 0 - 5 0.7 0.00 - - poor 0.00 0.99 −0.993 −0.007 0.99
Methadone N07B 0 - 1 0.1 0.00 - - poor 0.00 0.99 −0.999 −0.001 0.99
Antiparasitic products
Antiprotozoals and
antinematodals
P01 0 - 2 0.3 0.00 - - poor 0.00 0.99 −0.997 −0.003 0.99
Respiratory system
Medications for
obstructive airway disease
R03 7 0.9 29 3.8 0.27 0.08; 0.46 fair 0.28 0.98 −0.953 −0.029 0.93
Adrenergic inhalants R03A 5 0.7 11 1.4 0.49 0.19; 0.80 moderate 0.50 0.99 −0.980 −0.008 0.98
Other inhalants R03B 1 0.1 22 2.9 0.08 −0.07; 0.24 slight 0.09 0.99 −0.970 −0.028 0.94
Adrenergics, systemic R03CA 1 0.1 0 - 0.00 - - poor 0.00 0.99 −0.999 0.001 0.99
Nasal decongestants
and other topical
R01A 2 0.3 0 - 0.00 - - poor 0.00 0.99 −0.997 0.003 0.99
Cough and cold
preparations
R05 5 0.7 0 - 0.00 - - poor 0.00 0.99 −0.993 0.007 0.99
Antihistamines for
systemic use
R06A 3 0.4 5 0.7 0.50 0.07; 0.92 moderate 0.50 0.99 −0.990 −0.003 0.99
a 95 % CI = 95 % Confidence Interval
b According to Landis and Koch [22]
c Anatomical Therapeutic and Chemical classification code [20]
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Table 3 Comparison of questionnaire to prescription redemption database, by therapeutic class, Sensitivity, Specificity, Positive
Predictive Value, Negative Predictive Value, with 95 % confidence interval
Therapeutic class ATCa Sensitivity 95 % CIb Specificity 95 % CIb PPVc 95 % CIb NPVd 95 % CIb
Alimentary tract and metabolism
Medications for acid related disorders A02 0.15 0.13; 0.18 0.98 0.96; 0.98 0.37 0.22; 0.56 0.92 0.90; 0.94
Antacids A02A 0.18 0.15; 0.21 0.98 0.97; 0.99 0.24 0.11; 0.45 0.97 0.95; 0.98
Medications for peptic ulcer and
gastro-oesophageal reflux
A02B 0.10 0.08; 0.12 1.00 0.99; 1.00 0.57 0.25; 0.84 0.95 0.93; 0.96
Medications for functional
gastrointestinal disorders
A03 - - - 0.98 0.97; 0.99 0.00 0.00; 0.24 1.00 0.99; 1.00
Bile and liver therapy A05 0.33 0.30; 0.37 1.00 0.99; 1.00 0.50 0.09; 0.91 1.00 0.99; 1.00
Laxatives and antidiarrheals A06 0.00 - - 0.99 0.99; 1.00 0.00 0.00; 0.49 1.00 0.99; 1.00
Insulin A10A 0.33 0.30; 0.37 1.00 1.00; 1.00 1.00 0.21; 1.00 1.00 0.99; 1.00
Vitamins and mineral supplements A11, A12 0.00 - - 0.98 0.96; 0.99 0.00 0.00; 0.18 0.99 0.98; 1.00
Blood and blood forming organs
Antithrombotic agents B01 0.61 0.57; 0.64 0.99 0.99; 1.00 0.83 0.64; 0.93 0.98 0.97; 0.99
Heparins B01AB 0.50 0.46; 0.54 1.00 0.99; 1.00 0.86 0.60; 0.96 0.98 0.97; 0.99
Platelet aggregation inhibitors B01AC 0.83 0.81; 0.86 0.99 0.99; 1.00 0.71 0.45; 0.88 1.00 0.99; 1.00
Antihemorrhagics B02 0.00 - - 1.00 0.99; 1.00 - - - 0.99 0.98; 1.00
Iron B03A 0.60 0.56; 0.63 0.88 0.85; 0.90 0.66 0.59; 0.72 0.84 0.81; 0.87
Folic acid B03B 0.44 0.41; 0.48 0.68 0.65; 0.71 0.36 0.30; 0.42 0.75 0.71; 0.79
Solutions B05BB 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Cardiovascular system
Antihypertensive medications C02, C07, C08, C09A 0.75 0.72; 0.78 1.00 1.00; 1.00 1.00 0.61; 1.00 1.00 0.99; 1.00
Methyldopa C02 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Beta-blocking agents C07 1.00 1.00; 1.00 1.00 1.00; 1.00 1.00 0.44; 1.00 1.00 0.99; 1.00
Calcium channel blockers C08 0.71 0.68; 0.75 1.00 1.00; 1.00 1.00 0.57; 1.00 1.00 0.99; 1.00
Ace inhibitors C09A 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Lipid modifying agents C10A 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Diuretics C03 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Vasoprotectives C05C - - - 1.00 0.99; 1.00 0.00 0.00; 0.66 1.00 1.00; 1.00
Genito urinary system and sex hormones
Gynaecological antiinfectives and
antiseptics
G01A - - - 0.99 0.98; 1.00 0.00 0.00; 0.35 1.00 0.99; 1.00
Sympathomimetics, labour repressants G02CA 1.00 1.00; 1.00 0.99 0.98; 0.99 0.10 0.02; 0.40 1.00 0.99; 1.00
Prolactin inhibitors G02CB 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Hormonal contraceptives G03A 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Estrogens G03C 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Progestogens G03D 0.17 0.15; 0.20 1.00 0.99; 1.00 0.94 0.74; 0.99 0.89 0.87; 0.91
Gonadotrophins G03G 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Systemic hormonal preparations
Glucocorticoid, systemic H02A 0.22 0.19; 0.25 1.00 0.99; 1.00 0.40 0.12; 0.77 0.99 0.98; 1.00
Thyroid preparations H03 0.82 0.79; 0.85 1.00 0.99; 1.00 0.91 0.78; 0.97 0.99 0.98; 1.00
Thyroid hormones H03A 0.82 0.79; 0.85 1.00 0.99; 1.00 0.97 0.85; 0.99 0.99 0.98; 1.00
Antithyroid preparations H03B - - - 1.00 0.99; 1.00 0.00 0.00; 0.66 1.00 1.00; 1.00
Anti-infective agents
Antibiotics, systemic J01 0.09 0.07; 0.11 0.99 0.98; 0.99 0.65 0.43; 0.82 0.82 0.79; 0.85
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that the low value of Kappa was influenced by the low to
very low prevalence of use in the population.
Several reasons may explain the level of agreement be-
tween self-reported data and prescription redemption re-
cords. The type of use affects the accuracy of recall, thus
women may recall more accurately medications taken
chronically or over longer periods than those taken oc-
casionally. Questionnaire design and question structure
influence recall [15, 16, 39]. Questions specific for indi-
vidual medications/therapeutic classes or for indication,
increase the percentage of affirmative answers [39];
memory aids increase the accuracy of reporting. In this
study, the questionnaire was self-administered, questions
were open and no memory aid was used. This limitation
may have contributed to decrease the positive agree-
ment, in particular for medications taken occasionally.
Antidepressants and methadone were prescribed but
not reported. In a recent study, use of antidepressants
was not reported by 22 % of users during the first
trimester and by 38 % during the second and third [40].
Noncompliance and prescription medication borrowing
or sharing [10] may also partially explain disagreement.
We did not consider the prescriptions redeemed be-
fore the conception date. However, women may have
redeemed a prescription before and taken the medica-
tion also after conception, partly explaining the discrep-
ancies between sources.
The database does not capture information on the use
of OTC, non-prescription or non-reimbursed medica-
tions and herbal preparations. However, their use may
have been reported in questionnaires, thus contributing
to discrepancy between sources. The estimated preva-
lence of OTC use by pregnant women is not negligible.
In the Netherlands, 12.5 % of pregnant women used
OTC medications [41]. In the USA, OTC acetamino-
phen, ibuprofen, and pseudoephedrine were used by at
least 65 %, 18 %, and 15 % of pregnant women, respect-
ively [42].
Moreover, women may report medications taken in the
hospital setting, not captured by prescription databases.
Table 3 Comparison of questionnaire to prescription redemption database, by therapeutic class, Sensitivity, Specificity, Positive
Predictive Value, Negative Predictive Value, with 95 % confidence interval (Continued)
Antimycotics, systemic J02 0.25 0.22; 0.28 1.00 1.00; 1.00 1.00 0.21; 1.00 1.00 0.99; 1.00
Antivirals, systemic J05 0.20 0.17; 0.23 1.00 1.00; 1.00 1.00 0.21; 1.00 0.99 0.99; 1.00
Immune sera and immunoglobulins J06B 0.00 - - 1.00 1.00; 1.00 - - - 0.99 0.98; 1.00
Musculo-skeletal system
Non-steroidal anti-inflammatory
drugs
M01A 0.00 - - 1.00 0.99; 1.00 0.00 0.00; 0.66 0.99 0.97; 0.99
Bisphosphonates M05B 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Nervous system
Non-opioid analgesics N02BE 0.00 - - 0.94 0.92; 0.95 0.00 0.00; 0.08 1.00 0.99; 1.00
Selective serotonin agonists N02CC 0.00 - - 1.00 0.99; 1.00 0.00 0.00; 0.79 1.00 0.99; 1.00
Antiepileptic medications N03 1.00 1.00; 1.00 1.00 1.00; 1.00 1.00 0.21; 1.00 1.00 1.00; 1.00
Antidepressants N06A 0.00 - - 1.00 1.00; 1.00 - - - 0.99 0.98; 1.00
Methadone N07B 0.00 - - 1.00 1.00; 1.00 - - - 1.00 0.99; 1.00
Antiparasitic products
Antiprotozoals and antinematodals P01 0.00 - - - 1.00; 1.00 - - - 1.00 0.99; 1.00
Respiratory system
Medications for obstructive airway
disease
R03 0.17 0.14; 0.19 1.00 0.99; 1.00 0.83 0.44; 0.97 0.97 0.95; 0.98
Adrenergic, inhalants R03A 0.36 0.33; 0.40 1.00 1.00; 1.00 1.00 0.51; 1.00 0.99 0.98; 1.00
Other inhalants R03B 0.04 0.03; 0.06 1.00 1.00; 1.00 1.00 0.21; 1.00 0.97 0.96; 0.98
Adrenergics, systemic R03CA - - - 1.00 0.99; 1.00 0.00 0.00; 0.79 1.00 1.00; 1.00
Nasal decongestants and other
topical
R01A - - - 1.00 0.99; 1.00 0.00 0.00; 0.66 1.00 1.00; 1.00
Cough and cold preparations R05 - - - 0.99 0.98; 1.00 0.00 0.00; 0.43 1.00 0.99; 1.00
Antihistamines for systemic use R06A 0.40 0.37; 0.44 1.00 0.99; 1.00 0.67 0.21; 0.94 1.00 0.99; 1.00
aAnatomical Therapeutic and Chemical ATC classification code [20]
b95 % CI = 95 % Confidence Interval
cPPV = Positive Predictive Value
dNPV = Negative Predictive Value
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Table 4 Odds ratio, with 95 % confidence interval, of having at least one agreement between questionnaire and prescription
redemption database
Agreement between
questionnaire and databasea
At least 1
(N = 266)
None
(N = 375)
Univariate Multivariatea Multivariateb
n % n % Odds
Ratio
95 % CIb Odds
Ratio
95 % CIb Odds
Ratio
95 % CIb
Age at delivery (years)
<25 20 7.6 18 4.8 1.71 0.87; 3.39 2.25 1.06; 4.79 2.11 0.90; 4.93
25-29 27 10.1 61 16.3 0.68 0.41; 1.14 0.67 0.39; 1.14 0.57 0.31; 1.04
30-34c 110 41.3 170 45.3 1.00 - - 1.00 - - 1.00 - -
35-39 81 30.4 106 28.3 1.18 0.81; 1.72 1.33 0.90; 1.97 0.97 0.62; 1.52
40+ 28 10.6 20 5.3 2.16 1.16; 4.03 2.25 1.19; 4.26 2.34 1.15; 4.76
Country of origina
Italyc 245 92.1 341 90.9 1.00 - - 1.00 - - 1.00 - -
Other 19 7.1 30 8.0 0.88 0.48; 1.60 0.88 0.46; 1.67 0.83 0.30; 1.63
Level of education
< High school 39 14.7 71 19.0 0.59 0.37; 0.95 0.64 0.38; 1.08 0.64 0.35; 1.19
High school 118 44.4 186 49.7 0.69 0.48; 0.97 0.75 0.53; 1.09 0.89 0.59; 1.35
Universityc 108 40.6 117 31.3 1.00 - - 1.00 - - 1.00 - -
Smoking statusa
Ex-smoker, having quit during or after pregnancy 17 6.4 41 10.9 0.50 0.27; 0.91 0.48 0.26; 0.90 0.61 0.30; 1.24
Ex-smoker, having quit before pregnancy 56 21.2 80 21.3 0.85 0.57; 1.26 0.85 0.56; 1.29 0.91 0.57; 1.45
Current smoker 19 7.2 40 10.7 0.57 0.32; 1.03 0.66 0.36; 1.21 0.78 0.39; 1.56
Never smokerc 172 65.1 208 55.5 1.00 - - 1.00 - - 1.00 - -
Prior pregnancies
None 138 51.9 165 44.0 1.37 1.00; 1.88 1.50 1.07; 2.11 1.52 1.03; 2.24
At least onec 128 48.1 210 56.0 1.00 - - 1.00 - - 1.00 - -
Comorbidities during pregnancyd
At least one 202 75.9 286 76.3 1.79 1.25; 2.55 1.55 1.01; 2.37 1.10 0.66; 1.81
Nonec 61 22.9 89 23.7 1.00 - - 1.00 - - 1.00 - -
Number of medications reported in questionnaire
0 78 29.3 269 71.7 0.26 0.17; 0.39 - - - - 0.26 0.17; 0.41
1c 80 30.1 72 19.2 1.00 - - - - - - 1.00 - -
2 65 24.4 23 6.1 2.54 1.43; 4.51 - - - - 2.53 1.39; 4.59
3 or more 43 16.2 11 2.9 3.52 1.69; 7.34 - - - - 3.81 1.74; 8.34
Marital status
Marriedc 242 91.0 332 88.5 1.00 - - - - - - - - - -
Single 23 8.6 38 10.1 0.83 0.48; 1.43 - - - - - - - -
Time of questionnaire completion
Pre-delivery 127 47.7 204 54.4 0.77 0.56; 1.05 - - - - - - - -
Post-deliveryc 139 52.3 171 45.6 1.00 - - - - - - - - - -
Prenatal care visits (number)
<7 47 17.7 75 20.0 0.89 0.54; 1.47 - - - - - - - -
7 41 15.4 57 15.2 0.96 0.60; 1.52 - - - - - - - -
8 52 19.5 75 20.0 0.92 0.61; 1.41 - - - - - - - -
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The result for progestogens can be partly explained by in-
hospital use, e.g. for the risk of abortion.
In prior studies, the recall of medications taken during
the pregnancy was lower when assessed post-delivery vs.
pre-delivery [43, 44]. The recall time span was several
months to eight years. In our cohort, the agreement did
not vary according to the time of questionnaire comple-
tion. The recall time span in our study was much
shorter, median 30 days (25°-75° percentile 21–45 days).
This result confirms that the recall of medication use
during pregnancy is higher when data is collected shortly
after the delivery.
Women sociodemographic characteristics, health be-
haviours and conditions influenced the probability of
agreement. The agreement was less likely in immigrant
women, those with less than university education and
current or ex-smokers. Recall accuracy has been posi-
tively associated to maternal education [13, 44] and
negatively to smoking during pregnancy [13, 29]. Smok-
ing during pregnancy has been positively associated with
poor attention for health, for instance women smokers
more frequently do not take folic supplementation [45]
and have low adherence to psychotropic medications
[46]. Smokers may therefore have a less accurate recall
of medications assumption in pregnancy.
In our study, agreement was more likely in primiparae,
women experiencing comorbidities during pregnancy
and those in the extreme age classes. Women at their
first pregnancy, with poorer health condition or aged
40 years or older, may be more concerned on the preg-
nancy outcome and have a more accurate recall.
Another study found that the recall certainty of dates of
analgesic use in pregnancy was positively associated with
maternal age [13].
The use of medications outside the coverage of the
dispensing database, such as herbal medications or vita-
min supplements, may be more frequent in subgroups
of immigrant and young adult women. This differential
use of medications not covered by the database may par-
tially explain the lower likelihood of agreement in immi-
grant women and in those aged 25 to 29 years.
The likelihood of agreement increases with increasing
number of medications reported. Women who use more
medications may be those with health problems in preg-
nancy; therefore, they may recall better the medications
used during it. The total number of medications has pre-
viously been positively associated with the recall accur-
acy of prescription analgesics use [13].
Databases do not always capture information on gesta-
tional age and date of delivery. Thus, the timing of ex-
posure relative to pregnancy cannot be evaluated. This
limitation hinders the use of databases for pregnancy re-
search. The accurate timing of pregnancy is of great
relevance for epidemiologic studies of exposures during
pregnancy, including medications, and maternal or foetal
and infant outcomes. We found a very high agreement
Table 4 Odds ratio, with 95 % confidence interval, of having at least one agreement between questionnaire and prescription
redemption database (Continued)
9 + c 126 47.4 168 44.8 1.00 - - - - - - - - - -
Ultrasound imaging during pregnancy (number)
<4 66 24.8 98 26.1 0.87 0.56; 1.33 - - - - - - - -
4 50 18.8 60 16.0 1.07 0.66; 1.73 - - - - - - - -
5-7 73 27.5 118 31.5 0.79 0.52; 1.21 - - - - - - - -
8 + c 77 28.9 99 26.4 1.00 - - - - - - - - - -
a Adjusted by age at delivery, level of education, prior pregnancies, smoking status, comorbidities during pregnancy, country of origin
b 95 % CI = 95 % confidence interval
c Reference category
d It includes the following comorbidities occurring only during the pregnancy or before and during the pregnancy: diabetes, asthma, allergy, epilepsy,
hypertension, vomit, hypothyroidism, hyperthyroidism, lupus, rheumatic diseases, urinary infections, infections, fever, seizures, anaemia, cardiovascular diseases,
and neurological diseases
Table 5 Agreement between self-reported questionnaire and birth certificate database information
Gestational age (weeks) Date of deliverya (day) Prenatal visits (number) Prenatal ultrasound examinations (number)
N % N % N % N %
Exact match 634 85.2 759 99.5 186 24.2 254 33.1
±1 100 13.4 4 0.5 234 30.5 185 24.1
±2 9 1.2 - - 106 13.8 89 11.6
±3+ 1 0.1 241 31.4 239 31.2
a The date of delivery was missing in the questionnaire for 4 women
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for gestational age and date of delivery between ques-
tionnaire data and birth certificate records. This result is
in line with a prior study, reporting a high agreement,
with positive predictive value >90 %, between birth cer-
tificate and medical record data for gestational age [47].
The additional value of this study to the existing lit-
erature on the agreement between self-reports and
database information on medication use during preg-
nancy includes the followings: (a) it was performed in
a cohort with information on women demographic
and socioeconomic characteristics, and it could, there-
fore, assess the factors associated with agreement; (b)
in measuring agreement, the prevalence of the medi-
cation use was taken into account through the
PABAK calculation; (c) the study evaluated in the
same cohort both the agreement for medication use
and for gestational age and date of delivery - the lat-
ter being crucial for evaluating the reliability of data
on the timing of pregnancy.
A strength of this study is that all the women in the
cohort were linked to dispensing and birth certificate re-
cords, without omissions of specific population sub-
groups (e.g. low socioeconomic level or immigrant
status), confirming the high quality of FVG databases.
Conclusions
The agreement between self-reports and prescription re-
demption data was high to very high for medications
used for chronic conditions. Our findings confirm that
maternal reports and prescription redemption data are
complementary to each other to increase the reliability
of information on the use of medications during preg-
nancy. Future studies using large administrative data
should be considered to assess exposure also with a self-
reported questionnaire in a subsample as an internal val-
idation study. The results of this validation study could
be used, e.g. in sensitivity analysis, to take into account
the impact of possible exposure misclassification, on the
association with the outcome.
To assess the use of medications not captured by data-
base, such as OTC, herbal preparations, medications not
reimbursed or used in the hospital setting, other sources
should be considered, such as primary care or hospital
electronic medical records.
The method choice of interview and questionnaire de-
sign should account for maternal factors affecting recall,
such as sociodemographic and health behaviours, in the
target population.
We found a very high agreement for gestational age
and date of delivery between maternal reports and
birth certificate database. This result suggests that
birth certificates provide reliable data on the timing
of pregnancy.
Our results show that FVG health databases are a
valuable source of data for pregnancy research and for
studies on the safety of medications during pregnancy.
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